In addition, pladienolide B treatment decreases the expression of In1-Ghrelin, an oncogenic splice variant of Ghrelin, suggesting that SF3B1 or the SF3b complex associates with alternative splicing of Ghrelin. Supporting these findings, pladienolide B treatment is indicated to suppress the proliferation, survival and migration of prostate cancer cells [103]. Here, SF3B1 is linked to prostate carcinoma.